John R. Glass files SEC Form 4 disclosures for PROVECTUS BIOPHARMACEUTICALS, INC.. They have made 1 open-market trade across 1 company since 2017, most recently 2017-12-14.
CIK 0001672946
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2017, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PVCT | 200,000 | $11K |
Shares reported on the most recent Form 4, priced at the 2017-12-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PVCT | BUY | 2017-12-14 | 2017-12-18 | $0.05 | $10K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.